LUNG Projected Dividend Yield

Pulmonx Corp ( NASDAQ : LUNG )

Pulmonx is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Co.'s solution, which is comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. Co.'s solution is designed to address the need for for patients with severe emphysema, providing bronchoscopic lung volume reduction without surgery and its associated risks.

20 YEAR PERFORMANCE RESULTS